751 related articles for article (PubMed ID: 18195029)
1. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
3. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
Mazumder S; Maji M; Ali N
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
[TBL] [Abstract][Full Text] [Related]
4. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
5. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.
Sabur A; Bhowmick S; Chhajer R; Ejazi SA; Didwania N; Asad M; Bhattacharyya A; Sinha U; Ali N
Front Immunol; 2018; 9():18. PubMed ID: 29441060
[TBL] [Abstract][Full Text] [Related]
7. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
9. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
11. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
12. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
13. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
[TBL] [Abstract][Full Text] [Related]
14. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
Ravindran R; Bhowmick S; Das A; Ali N
BMC Microbiol; 2010 Jun; 10():181. PubMed ID: 20576102
[TBL] [Abstract][Full Text] [Related]
15. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.
Mazumder S; Maji M; Das A; Ali N
PLoS One; 2011 Feb; 6(2):e14644. PubMed ID: 21311597
[TBL] [Abstract][Full Text] [Related]
16. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
17. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
Bhowmick S; Ravindran R; Ali N
BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
[TBL] [Abstract][Full Text] [Related]
18. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.
Helou DG; Mauras A; Fasquelle F; Lanza JS; Loiseau PM; Betbeder D; Cojean S
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009627. PubMed ID: 34403413
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.
Afrin F; Rajesh R; Anam K; Gopinath M; Pal S; Ali N
Infect Immun; 2002 Dec; 70(12):6697-706. PubMed ID: 12438344
[TBL] [Abstract][Full Text] [Related]
20. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
